Three directors resign after D&O insurance lapse; $550K convertible note issued

Sigyn Therapeutics, Inc.

Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.
Entered agreement with Lambda Venture Partners for up to $550K principal, $500K funding; first tranche $110K/$100K.
Notes bear 8% interest, one-year term, convertible at 35% discount to lowest traded price in prior 10 days.
No warrants issued; securities sold under Section 4(a)(2) exemption.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.